VPS35L

Across TCGA pan-cancer cohorts, VPS35L Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated VPS35L data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher VPS35L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VPS35L expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, LUAD, and PRAD are the cancer types where VPS35L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	30	view →
LUAD	OS	Median	II,III,IV	0.157	0.682	<.001	25	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	OS	Median	All	0.394	0.687	.010	6	view →
BLCA	OS	Median	All	0.196	0.592	.042	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.875	0.557	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

VPS35L–ESCA (OS)

Open the ESCA breakdown →